Health-related Quality of Life and Comorbidities in Danish Patients With Idiopathic Pulmonary Fibrosis - a Nationwide Follow-up
- Conditions
- Idiopathic Pulmonary Fibrosis
- Registration Number
- NCT02818712
- Lead Sponsor
- Aarhus University Hospital
- Brief Summary
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a high mortality. Health-related quality of life (HRQL) is impaired in patients with IPF. Little is known about the properties of recently developed HRQL questionnaires and about the longitudinal changes in HRQL, including factors with an impact on HRQL. Comorbidities have an impact on patients with IPF, but reports differ in incidence and prevalence. The impact of comorbidities on HRQL and disease progression has only been studied sparsely. Also, the association between biomarkers and disease progression need to be examined further.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 150
- A clinical diagnosis of IPF
- Signed informed consent
- Clinical, radiological or histological findings inconsistent with a diagnosis of IPF
- Inability or unwillingness to adhere to the study
- Active on lung transplantation list
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Health-related quality of life Baseline, 2 weeks, 6 months, 12 months, 24 months, 36 months Changes in King's Brief Interstitial Lung Disease questionnaire
Number and type of comorbidities Change/incidence at 6 months, 12 months, 24 months and 36 months Incidence of new comorbidities after 6 months, 12 months, 24 months and 36 months
- Secondary Outcome Measures
Name Time Method 6-minute walk test Baseline, 6 months, 12 months, 24 months, 36 months Change in 6-minute walk test
Lung function tests Baseline, 6 months, 12 months, 24 months, 36 months Change in diffusion capacity for carbon monoxide
Disease progression Baseline, 6 months, 12 months, 24 months, 36 months Changes in use of supplementary oxygen
Progression in serum/plasma biomarker levels Baseline, 6 months, 12 months, 24 months, 36 months Increase or decrease in serum/plasma biomarker levels
Health-related quality of life Baseline, 6 months, 12 months, 24 months, 36 months Changes in University of California San Diego Shortness Of Breath Questionnaire
Trial Locations
- Locations (3)
Aarhus University Hosptial
🇩🇰Aarhus C, Denmark
Gentofte Hospital
🇩🇰Hellerup, Denmark
Odense University Hospital
🇩🇰Odense, Denmark